An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...

Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00.

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

The company will report earnings before the open on Jan. 29 Israel-based pharmaceutical giant Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is preparing for its latest quarterly earnings report, due ...

Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Anti-Fungal Therapy Market. The global anti-fungal therapy market is set to experience significant growth, with a projected ...

The drugs listed are in alphabetical order. Bendamustine hydrochloride injection: Apotex on Jan. 27 reported the discontinuation of both the 25 mg and 100 mg presentations of bendamustine ...

Bank Leumi (TASE: LUMI) led the market today, rising 0.79% on the day's biggest trading turnover. Mizrahi Tefahot Bank rose 0.60%, Bank Hapoalim (TASE: POLI) rose 0.88%, and Israel Discount Bank (TASE ...

As Sandoz gears up to launch of one of the most anticipated biosimilars of the year, the company could face near-term ...

© 2025 American City Business Journals. All rights reserved. Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement ...